Self-Rated Communication-Related Quality of Life of Individuals With Oromandibular Dystonia Receiving Botulinum Toxin Injections Purpose In this preliminary study, we examined self-rated communication-related quality of life (CR-QoL) of 10 control participants and 10 individuals with oromandibular dystonia (OMD) and dysarthria receiving therapeutic botulinum toxin (BoNT-A) injections. Method Participants with OMD and associated dysarthria self-rated CR-QoL pre- and post- BoNT-A injection using the ... Research Note
Research Note  |   June 22, 2017
Self-Rated Communication-Related Quality of Life of Individuals With Oromandibular Dystonia Receiving Botulinum Toxin Injections
 
Author Affiliations & Notes
  • Allyson D. Page
    School of Communication Sciences and Disorders, Western University, London, ON, Canada
    Health and Rehabilitation Sciences, Western University, London, ON, Canada
  • Lauren Siegel
    Health and Rehabilitation Sciences, Western University, London, ON, Canada
  • Mandar Jog
    Department of Clinical Neurological Sciences, Western University, London, ON, Canada
  • Disclosure: The authors have declared that no competing interests existed at the time of publication.
    Disclosure: The authors have declared that no competing interests existed at the time of publication. ×
  • Correspondence to Allyson D. Page: allyson.page@uwo.ca
  • Editor: Nancy Solomon
    Editor: Nancy Solomon×
  • Associate Editor: Kathryn Yorkston
    Associate Editor: Kathryn Yorkston×
Article Information
Speech, Voice & Prosodic Disorders / Dysarthria / Research Issues, Methods & Evidence-Based Practice / ASHA News & Member Stories / Speech, Voice & Prosody / Special Issue: Selected Papers From the 2016 Conference on Motor Speech—Clinical Science and Implications / Research Notes
Research Note   |   June 22, 2017
Self-Rated Communication-Related Quality of Life of Individuals With Oromandibular Dystonia Receiving Botulinum Toxin Injections
American Journal of Speech-Language Pathology, June 2017, Vol. 26, 674-681. doi:10.1044/2017_AJSLP-16-0098
History: Received June 14, 2016 , Revised October 25, 2016 , Accepted November 29, 2016
 
American Journal of Speech-Language Pathology, June 2017, Vol. 26, 674-681. doi:10.1044/2017_AJSLP-16-0098
History: Received June 14, 2016; Revised October 25, 2016; Accepted November 29, 2016

Purpose In this preliminary study, we examined self-rated communication-related quality of life (CR-QoL) of 10 control participants and 10 individuals with oromandibular dystonia (OMD) and dysarthria receiving therapeutic botulinum toxin (BoNT-A) injections.

Method Participants with OMD and associated dysarthria self-rated CR-QoL pre- and post- BoNT-A injection using the American Speech-Language-Hearing Association's Quality of Communication Life Scale (ASHA QCL; Paul et al., 2004). Control participants self-rated CR-QoL during a single experimental visit.

Results Significant differences were found between control participants and participants with OMD on ratings of CR-QoL across all 5 domains and subdomains of the ASHA QCL. No significant differences in CR-QoL were found over the course of the BoNT-A treatment cycle.

Conclusions CR-QoL was rated lower by participants with OMD as compared with control participants across all ASHA QCL domains/subdomains with “socialization/activities” and “confidence/self-concept” having the largest effect sizes. No differences in CR-QoL were found over the course of the treatment cycle. We advocate for outcome measures that include patient report. The use of patient-reported outcome measures in conjunction with objective or impairment-based outcome measures can help inform meaningful clinical indicators of treatment success. This study adds novel information that may aid our understanding of the experience of living with OMD in this underserviced clinical population.

Order a Subscription
Pay Per View
Entire American Journal of Speech-Language Pathology content & archive
24-hour access
This Article
24-hour access